TRV045, a novel, selective S1PR₁ modulator, is efficacious in reversing neuropathic pain without affecting lymphocyte trafficking

Michael S. Kramer, M.S., Stefania Risso, Ph.D., Michael J.Fossler, Pharm.D., Ph.D., Mark A. Demitrack, M.D. Trevena, Inc., Chesterbrook, PA

BACKGROUND

- Chemotherapy-induced peripheral neuropathy (CIPN) is a neuropathic pain condition that occurs in up to 70% of oncology patients undergoing chemotherapy and can result from a variety of chemotherapeutic agents (1)
- Diabetic peripheral neuropathy (DPN) is a complication of diabetes mellitus; nearly 50% of adults with diabetes will suffer from DPN during their lifetime (2)
- For these debilitating conditions there is still an unmet medical need for prophylactic and symptomatic treatment to effectively alleviate the symptoms
- Recent publications (3,4) have suggested a beneficial role for non-selective sphingosine 1-phosphate receptor subtype 1 (S1PR₁) modulators in treating neuropathic pain
- However, S1PR modulators available on the market, including fingolimod (GILENYA®) are not selective for S1PR₁ (5), and, importantly, affect lymphocyte trafficking (6), limiting their utility for the treatment of neuropathic pain
- We report here the analgesic properties of a new chemical entity, TRV045, in rodent models of neuropathic pain and demonstrate the lack of effect on lymphocyte trafficking in rodents and non-human primates

OBJECTIVES

- To evaluate the potency and selectivity of TRV045 for S1PR₁
- To evaluate the analgesic properties of TRV045 in a mouse CIPN model and a rat DPN model
- To evaluate the effects of TRV045 on lymphocyte trafficking in rats and monkeys

METHODS

Figure 1. Mouse chemotherapy-induced peripheral neuropathy (CIPN) Dosing of TRV045 (s.c.) or fingolimod (p.o.)— Paclitaxel (6 mg/kg i.p.) Von Frey testing 30 min post-dose





Figure 2. Rat streptozotocin (STZ)-induced diabetic neuropathy



Lymphocytes counts were determined in male C57BL/6 mice (n=6 to 12/group) following 3 consecutive days of dosing with vehicle, 3.7 mg/kg TRV045 s.c., or 0.03 mg/kg fingolimod p.o. Lymphocyte counts were also determined in male cynomolgus monkeys (n=3) following p.o. dosing with saline, vehicle or 60 mg/kg TRV045.

RESULTS





Figure 4. TRV045 reverses paclitaxel-induced hypersensitivity in the mouse CIPN assay with efficacy comparable to fingolimod (FTY)



Statistical analysis: * P<0.05; *** P<0.001, treatments vs. Pac/Veh group, one-way ANOVA followed by Dunnett's test

Figure 5. TRV045 reverses STZ-induced diabetic neuropathy in rats with efficacy comparable to gabapentin (gbp)






Figure 6. Unlike other S1PR₁ modulators such as fingolimod, TRV045 does not cause lymphopenia in mice



3.7 mg/kg dose is >10-fold higher than the ED_{50} dose in the mouse CIPN study Statistical analysis: ** P<0.01, treatments vs. vehicle group, one-way ANOVA followed by Dunnett's test

Figure 7. TRV045 does not cause lymphopenia in cynomolgus monkeys



CONCLUSIONS

TRV045 is a selective S1P1R₁ modulator that is an effective analgesic in rodent models of neuropathic pain

Our findings confirm that the modulation of the S1P/S1PR₁ axis is a promising therapeutic target in reversing chemotherapy-induced peripheral neuropathy and show for the first time that modulation of S1PR₁ might reverse diabetic neuropathic pain

also demonstrate that TRV045 does not cause lymphopenia and therefore may provide a new, safe, and specific therapeutic option for the treatment of neuropathic pain

References

- 1. Piccolo and Kolesar, 2014, Am J Health-Syst Pharm, 71: 19-25
- 2. Hicks and Selvin, 2019, Curr Diab Rep, 19 (10):86
- 3. Janes et al., 2014, JBC, 289: 21082-21097
- 4. Sim-Selley et al., 2018, J Pharmacol Exp Ther, 366: 509-518
- 5. Chew et al., 2016, Pharm Res, 113: 521-32
- 6. Adachi and Chiba, 2007, Perspec Med Chem, 1:11-23

Disclosure

TRV045 is an investigational drug developed by Trevena, Inc. Funding for this work was provided by Trevena, Inc.

Dunnett's test